No Admire for Aducanumab From FDA Advisers

No Admire for Aducanumab From FDA Advisers

An FDA advisory committee voted overwhelmingly in opposition to the information offered about the controversial Alzheimer’s drug candidate aducanumab Friday. The agency’s Peripheral and Central Worried Machine (PCNS) Medicine Advisory Committee acknowledged the sure results considered in regarded as one…